The use of immune checkpoint inhibitors (ICIs) is also supported by the increased expression of PD‐L1/PD‐1 in tumor‐infiltrating lymphocytes from patients with lymphoma and increased PD‐1 expression in circulating T cells from patients with CLL.11 Here, CD274 is linked to B-cell chronic lymphocytic leukemia.